{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:20:34Z","timestamp":1761175234014,"version":"build-2065373602"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-025-03373-9","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:14:46Z","timestamp":1761120886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of clinical factors and season on inflammatory cytokines in biologic-treated and untreated asthma"],"prefix":"10.1186","volume":"26","author":[{"given":"Tanawin","family":"Nopsopon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cabrera-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pui Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailey E.","family":"Brodeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan E.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"LeSon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayobami","family":"Akenroye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"3373_CR1","doi-asserted-by":"publisher","unstructured":"Enilari O, Sinha S. The global impact of asthma in adult populations. Ann Glob Health Jan. 2019;22(1). https:\/\/doi.org\/10.5334\/aogh.2412.","DOI":"10.5334\/aogh.2412"},{"issue":"2","key":"3373_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","volume":"135","author":"ML Fajt","year":"2015","unstructured":"Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. The J Allergy Clin Immunology. 2015;135(2):299\u2013310. https:\/\/doi.org\/10.1016\/j.jaci.2014.12.1871.","journal-title":"The J Allergy Clin Immunology"},{"issue":"3","key":"3373_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaip.2022.10.047","volume":"11","author":"A Akenroye","year":"2023","unstructured":"Akenroye A, Ryan T, McGill A, Zhou G, Shier J, Segal J. Switch patterns in a cohort of individuals with asthma who received Omalizumab or mepolizumab therapy. J Allergy Clin Immunol Pract Mar. 2023;11(3):946\u2013e9481. https:\/\/doi.org\/10.1016\/j.jaip.2022.10.047.","journal-title":"J Allergy Clin Immunol Pract Mar"},{"issue":"7","key":"3373_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1164\/rccm.202009-3631CI","volume":"1","author":"SE Wenzel","year":"2021","unstructured":"Wenzel SE. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2021;1(7):809\u201321. https:\/\/doi.org\/10.1164\/rccm.202009-3631CI.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3373_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12931-023-02620-1","volume":"6","author":"A Akenroye","year":"2023","unstructured":"Akenroye A, Nopsopon T, Cho L, Moll M, Weiss ST. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses. Respir Res. 2023;6(1):305. https:\/\/doi.org\/10.1186\/s12931-023-02620-1.","journal-title":"Respir Res"},{"key":"3373_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00931-2023","author":"T Nopsopon","year":"2024","unstructured":"Nopsopon T, Chen Y, Chen Q, et al. Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma. ERJ Open Res. 2024. https:\/\/doi.org\/10.1183\/23120541.00931-2023.","journal-title":"ERJ Open Res"},{"issue":"3","key":"3373_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","volume":"1","author":"R Djukanovi\u0107","year":"2024","unstructured":"Djukanovi\u0107 R, Brinkman P, Kolmert J, et al. Biomarker predictors of clinical efficacy of the anti-IgE biologic Omalizumab in severe asthma in adults: results of the somosa study. Am J Respir Crit Care Med. 2024;1(3):288\u201397. https:\/\/doi.org\/10.1164\/rccm.202310-1730OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3373_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60864-3","volume":"6","author":"A Akenroye","year":"2024","unstructured":"Akenroye A, Nopsopon T, Hacker JJ, Laidlaw TM. Ratio of plasma IL-13\/TNF- \u221d and CXCL10\/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level. Sci Rep. 2024;6(1):10404. https:\/\/doi.org\/10.1038\/s41598-024-60864-3.","journal-title":"Sci Rep"},{"issue":"7","key":"3373_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/s2213-2600(16)30048-0","volume":"4","author":"MC Peters","year":"2016","unstructured":"Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574\u201384. https:\/\/doi.org\/10.1016\/s2213-2600(16)30048-0.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3373_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1164\/rccm.201909-1813OC","volume":"1","author":"MC Peters","year":"2020","unstructured":"Peters MC, Mauger D, Ross KR, et al. Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency. Am J Respir Crit Care Med. 2020;1(7):973\u201382. https:\/\/doi.org\/10.1164\/rccm.201909-1813OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3373_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaci.2019.08.031","volume":"145","author":"X Li","year":"2020","unstructured":"Li X, Hastie AT, Peters MC, et al. Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. J Allergy Clin Immunol. 2020;145(1):430\u20133. https:\/\/doi.org\/10.1016\/j.jaci.2019.08.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"3373_CR12","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1172\/jci36130","volume":"118","author":"PJ Barnes","year":"2008","unstructured":"Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546\u201356. https:\/\/doi.org\/10.1172\/jci36130.","journal-title":"J Clin Invest"},{"issue":"4","key":"3373_CR13","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","volume":"155","author":"A Akenroye","year":"2025","unstructured":"Akenroye A, Boyce JA, Kita H. Targeting alarmins in asthma: from bench to clinic. J Allergy Clin Immunol. 2025;155(4):1133\u201348. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.017.","journal-title":"J Allergy Clin Immunol"},{"key":"3373_CR14","doi-asserted-by":"publisher","unstructured":"Castro VM, Gainer V, Wattanasin N, et al. The mass General Brigham biobank portal: an i2b2-based data repository linking disparate and high-dimensional patient data to support multimodal analytics. J Am Med Inform Assoc. 2022(4). https:\/\/doi.org\/10.1093\/jamia\/ocab264.","DOI":"10.1093\/jamia\/ocab264"},{"issue":"6","key":"3373_CR15","doi-asserted-by":"publisher","first-page":"E999","DOI":"10.1210\/jc.2013-4232","volume":"99","author":"P Ghosh","year":"2014","unstructured":"Ghosh P, Vaidya A, Sahoo R, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab Jun. 2014;99(6):E999\u20131006. https:\/\/doi.org\/10.1210\/jc.2013-4232.","journal-title":"J Clin Endocrinol Metab Jun"},{"issue":"9","key":"3373_CR16","doi-asserted-by":"publisher","first-page":"e5690","DOI":"10.7759\/cureus.5690","volume":"18","author":"N Johnson","year":"2019","unstructured":"Johnson N, Varughese B, De La Torre MA, Surani SR, Udeani G. A review of respiratory biologic agents in severe asthma. Cureus Sep. 2019;18(9):e5690. https:\/\/doi.org\/10.7759\/cureus.5690.","journal-title":"Cureus Sep"},{"issue":"3","key":"3373_CR17","first-page":"14","volume":"81","author":"General Assembly of the World Medical Association","year":"2014","unstructured":"General Assembly of the World Medical Association. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent Summer. 2014;81(3):14\u20138.","journal-title":"J Am Coll Dent Summer"},{"issue":"4","key":"3373_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS ONE"},{"issue":"7982","key":"3373_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622(7982):348\u201358. https:\/\/doi.org\/10.1038\/s41586-023-06563-x.","journal-title":"Nature"},{"key":"3373_CR20","doi-asserted-by":"publisher","unstructured":"Lazar C, Gatto L, Ferro M, Bruley C, Burger T. Accounting for the multiple natures of missing values in label-free quantitative proteomics data sets to compare imputation strategies. J Proteome Res. 2016(4). https:\/\/doi.org\/10.1021\/acs.jproteome.5b00981.","DOI":"10.1021\/acs.jproteome.5b00981"},{"issue":"1","key":"3373_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-19120-0","volume":"8","author":"R Wei","year":"2018","unstructured":"Wei R, Wang J, Su M, et al. Missing value imputation approach for mass spectrometry-based metabolomics data. Sci Rep. 2018;8(1):663. https:\/\/doi.org\/10.1038\/s41598-017-19120-0.","journal-title":"Sci Rep"},{"issue":"1","key":"3373_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72664-6","volume":"23","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Wong L, Goh WWB. How to do quantile normalization correctly for gene expression data analyses. Sci Rep. 2020;23(1):15534. https:\/\/doi.org\/10.1038\/s41598-020-72664-6.","journal-title":"Sci Rep"},{"issue":"1","key":"3373_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81279-4","volume":"11","author":"L Jin","year":"2021","unstructured":"Jin L, Bi Y, Hu C, et al. A comparative study of evaluating missing value imputation methods in label-free proteomics. Sci Rep. 2021;11(1):1760. https:\/\/doi.org\/10.1038\/s41598-021-81279-4.","journal-title":"Sci Rep"},{"issue":"1","key":"3373_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04938-0","volume":"20","author":"M Shen","year":"2022","unstructured":"Shen M, Chang YT, Wu CT, et al. Comparative assessment and novel strategy on methods for imputing proteomics data. Sci Rep. 2022;20(1):1067. https:\/\/doi.org\/10.1038\/s41598-022-04938-0.","journal-title":"Sci Rep"},{"key":"3373_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12688\/wellcomeopenres.18482.2","volume":"7","author":"N Goulding","year":"2022","unstructured":"Goulding N, Goudswaard LJ, Hughes DA, et al. Inflammation proteomics datasets in the ALSPAC cohort. Wellcome Open Res. 2022;7:277. https:\/\/doi.org\/10.12688\/wellcomeopenres.18482.2.","journal-title":"Wellcome Open Res"},{"issue":"6","key":"3373_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"15","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;15(6):882\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034.","journal-title":"Bioinformatics"},{"issue":"7","key":"3373_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"20","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;20(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"key":"3373_CR28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00142-2021","author":"M Sparreman Mikus","year":"2022","unstructured":"Sparreman Mikus M, Kolmert J, Andersson LI, et al. Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to type-2 inflammation. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.00142-2021.","journal-title":"Eur Respir J"},{"issue":"2","key":"3373_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jaci.2018.05.026","volume":"143","author":"Z Jevnikar","year":"2019","unstructured":"Jevnikar Z, \u00d6stling J, Ax E, et al. Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. J Allergy Clin Immunol. 2019;143(2):577\u201390. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3373_CR30","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.jaci.2016.09.015","volume":"139","author":"PJ Busse","year":"2017","unstructured":"Busse PJ, Birmingham JM, Calatroni A, et al. Effect of aging on sputum inflammation and asthma control. J Allergy Clin Immunol Jun. 2017;139(6):1808\u2013e18186. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.015.","journal-title":"J Allergy Clin Immunol Jun"},{"issue":"5","key":"3373_CR31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","volume":"147","author":"E Israel","year":"2021","unstructured":"Israel E, Denlinger LC, Bacharier LB, et al. PrecISE: precision medicine in severe asthma: an adaptive platform trial with biomarker ascertainment. J Allergy Clin Immunol. 2021;147(5):1594\u2013601. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.037.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3373_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaci.2021.10.035","volume":"149","author":"SN Georas","year":"2022","unstructured":"Georas SN, Wright RJ, Ivanova A, et al. The precision interventions for severe and\/or Exacerbation-Prone (PrecISE) asthma network: an overview of network organization, procedures, and interventions. J Allergy Clin Immunol Feb. 2022;149(2):488\u2013e5169. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.035.","journal-title":"J Allergy Clin Immunol Feb"},{"issue":"3","key":"3373_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12238","volume":"13","author":"S Bj\u00f6rkander","year":"2023","unstructured":"Bj\u00f6rkander S, Klevebro S, Hernandez-Pacheco N, et al. Obese asthma phenotypes display distinct plasma biomarker profiles. Clin Transl Allergy. 2023;13(3):e12238. https:\/\/doi.org\/10.1002\/clt2.12238.","journal-title":"Clin Transl Allergy"},{"issue":"9","key":"3373_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217807","volume":"14","author":"EL Angulo","year":"2019","unstructured":"Angulo EL, McKernan EM, Fichtinger PS, Mathur SK. Comparison of IL-33 and IL-5 family mediated activation of human eosinophils. PLoS ONE. 2019;14(9):e0217807. https:\/\/doi.org\/10.1371\/journal.pone.0217807.","journal-title":"PLoS ONE"},{"issue":"6","key":"3373_CR35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","volume":"163","author":"C Moermans","year":"2023","unstructured":"Moermans C, Brion C, Bock G, et al. Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5. Chest. 2023;163(6):1368\u201379. https:\/\/doi.org\/10.1016\/j.chest.2023.01.037.","journal-title":"Chest"},{"issue":"12","key":"3373_CR36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/crj.13718","volume":"17","author":"Q Huang","year":"2023","unstructured":"Huang Q, Li Y, Li C, et al. Cigarette smoke aggravates asthma via altering airways inflammation phenotypes and remodelling. Clin Respir J. 2023;17(12):1316\u201327. https:\/\/doi.org\/10.1111\/crj.13718.","journal-title":"Clin Respir J"},{"key":"3373_CR37","doi-asserted-by":"publisher","unstructured":"Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med. Oct 2000;162(4 Pt 1):1355\u201360. https:\/\/doi.org\/10.1164\/ajrccm.162.4.9910097.","DOI":"10.1164\/ajrccm.162.4.9910097"},{"issue":"8000","key":"3373_CR38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41586-023-06968-8","volume":"626","author":"V Saint-Andr\u00e9","year":"2024","unstructured":"Saint-Andr\u00e9 V, Charbit B, Biton A, et al. Smoking changes adaptive immunity with persistent effects. Nature. 2024;626(8000):827\u201335. https:\/\/doi.org\/10.1038\/s41586-023-06968-8.","journal-title":"Nature"},{"issue":"26","key":"3373_CR39","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"27","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;27(26):2455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1304048.","journal-title":"N Engl J Med"},{"issue":"10039","key":"3373_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(16)30307-5.","journal-title":"Lancet"},{"issue":"3","key":"3373_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1164\/rccm.201609-1830OC","volume":"1","author":"RY Kim","year":"2017","unstructured":"Kim RY, Pinkerton JW, Essilfie AT, et al. Role for NLRP3 inflammasome-mediated, IL-1\u03b2-dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. 2017;1(3):283\u201397. https:\/\/doi.org\/10.1164\/rccm.201609-1830OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3373_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/thoraxjnl-2020-215979","volume":"77","author":"PS Pathinayake","year":"2022","unstructured":"Pathinayake PS, Waters DW, Nichol KS, et al. Endoplasmic reticulum-unfolded protein response signalling is altered in severe eosinophilic and neutrophilic asthma. Thorax. 2022;77(5):443\u201351. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215979.","journal-title":"Thorax"},{"issue":"2","key":"3373_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/all.13619","volume":"74","author":"HT Tan","year":"2019","unstructured":"Tan HT, Hagner S, Ruchti F, et al. Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. Allergy. 2019;74(2):294\u2013307. https:\/\/doi.org\/10.1111\/all.13619.","journal-title":"Allergy"},{"issue":"4","key":"3373_CR44","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2021.10.003","volume":"149","author":"JW Pinkerton","year":"2022","unstructured":"Pinkerton JW, Kim RY, Brown AC, et al. Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma. J Allergy Clin Immunol. 2022;149(4):1270\u201380. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"3373_CR45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389. https:\/\/doi.org\/10.1038\/s41577-019-0165-0.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3373_CR46","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.jaci.2017.03.018","volume":"139","author":"RS Peebles","year":"2017","unstructured":"Peebles RS. Is IL-1\u03b2 inhibition the next therapeutic target in asthma? J Allergy Clin Immunol. 2017;139(6):1788\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2017.03.018.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3373_CR47","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaci.2016.08.032","volume":"139","author":"W Liu","year":"2017","unstructured":"Liu W, Liu S, Verma M, et al. Mechanism of T(H)2\/T(H)17-predominant and neutrophilic T(H)2\/T(H)17-low subtypes of asthma. J Allergy Clin Immunol May. 2017;139(5):1548\u2013e15584. https:\/\/doi.org\/10.1016\/j.jaci.2016.08.032.","journal-title":"J Allergy Clin Immunol May"},{"issue":"1","key":"3373_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4049\/jimmunol.1100500","volume":"1","author":"JL Ather","year":"2011","unstructured":"Ather JL, Ckless K, Martin R, et al. Serum amyloid a activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol. 2011;1(1):64\u201373. https:\/\/doi.org\/10.4049\/jimmunol.1100500.","journal-title":"J Immunol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03373-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:14:47Z","timestamp":1761120887000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3373"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03373-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TN, JCP, PYL, KEB, EEH, CL, GH, SAC, and AA have no relevant conflicts of interest to disclose. NLL: received consulting fees from Amgen, Apogee, AstraZeneca, Avillion, Foresee, Genentech, GSK, Niox, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speakers bureau presentations from GSK, TEVA and Astra Zeneca; and travel support from Astra Zeneca, SANOFI, TEVA, Regeneron and GSK; her institution received research support from Amgen, AstraZeneca, Avillion, Bellus, Evidera, Gossamer Bio, Genentech, GSK, Janssen, Niox, Regeneron, Sanofi, Novartis and Teva. She is an honorary faculty member of Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role. STW: Has no conflicts related to content. Receives royalties from UpToDate and is on the board of Histolix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}